A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Essential Hypertension, Dyslipidemia
Interventions
DRUG

Fimasartan and Rosuvastatin

DRUG

Fimasartan

DRUG

Rosuvastatin

Trial Locations (26)

Unknown

Seoul university Bundang hospital, Bundang

Dong-A university hospital, Busan

Inje Heaundai Paik hospital, Busan

Inje university Busan Paik hospital, Busan

The Catholic university of Korea Daegu hospital, Daegu

DongGuk university Gyeongju hospital, Gyeongju

DongGuk university Ilsan hospital, Ilsan

Inje university Ilsan Paik hospital, Ilsan

Gachon university Gil medical center, Incheon

Inha university hospital, Incheon

Jeju national university hospital, Jeju City

JeonNam university hospital, JeonNam

ChungNam university hospital, Jungnam

DanGuk university hospital, Jungnam

Kyungbook National university hospital, Kyungbook

Gangnam Severance hospital, Seoul

Jeil hospital, Seoul

Korea university Anam hospital, Seoul

Korea university Guro hospital, Seoul

Kyunghee university hospital, Seoul

Samsung Seoul hospital, Seoul

Seoul national university hospital, Seoul

Severance hospital, Seoul

The Catholic university St. Mary hospital, Seoul

Aju university hospital, Suwon

YoungNam university hospital, YoungNam

All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT02166814 - A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia | Biotech Hunter | Biotech Hunter